Who gets dibs on in-demand medicines? Can you get a refund on an $8 billion buy? And what happens when sweetheart deals go bad?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT’s Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation. We also discuss a curious trend in biotech investing, the future of Illumina, and another sentencing in the Theranos saga.
Sponsored insight by GENENTECH, A MEMBER OF THE ROCHE GROUP
Pioneering approaches to caring for and addressing the diverse needs of people with blood diseases
Hematologic disorders comprise a vast category of diseases, and although some types can be managed to prevent symptoms or complications, others lead to a poor prognosis because the disease relapses or is refractory to treatment.
Scientists at Genentech are pursuing effective treatment options for patients with hematologic cancers and rare blood diseases at all stages of their journey, rethinking what is possible when it comes to standards of care and the treatment experience. Learn more about how research has made important strides in treating various types of blood diseases.
No comments